• Minicabecera4

Histocell and Ferrer announce that the preclinical studies of their traumatic spinal cord injury drug support its therapeutic potential (2)

Histocell laboratory

 

 

Histocell, specialist in cell therapy applied to regenerative medicine and Ferrer pharmaceutical company have presented the preclinical results of NeuroSave (FAB117-HC), a new advanced therapy for traumatic spinal cord injury. The data was presented at the International Spinal Cord Repair Conference (ISCORE) held in Barcelona in November with the participation of world-renowned specialists in the field of spinal cord injury.

 

The preclinical research was presented by Dr. Francisco Javier Rodríguez, a specialist at the Toledo Hospital for Paraplegics. He explained that "the drug, made by a type of adult stem cell specially designed to promote recovery from spinal cord injury (HC016 cells), has shown very positive results when administered in the acute phase directly in the damaged area of the spinal cord".

Phase I/II clinical trials with NeuroSave in patients with acute traumatic spinal cord injury are due to begin in the first quarter of 2016.

There are an estimated 2.5 million patients with spinal cord injury in the world and every year there are more than 130,000 new cases mostly among young people. The severity of the injury and the absence of effective treatments has a considerable impact on the quality of life of patients and their families. Experts say that the cost to society of a patient with spinal cord injury can be nine times greater than that attributable to such disabling diseases as dementia.